Importance Bladder cancer is a common malignancy in women and is the fourth most
common malignancy in men. Bladder cancer ranges from unaggressive and usually …

Abstract Background Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a
crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving …

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

Background Urothelial carcinomas of the upper urinary tract (UTUCs) are rare, with poorer
stage-for-stage prognosis than urothelial carcinomas of the urinary bladder. No international …

In a recent phase 3 randomized trial of 700 patients with advanced urothelial cancer
(JAVELIN Bladder 100; NCT02603432), avelumab/best supportive care (BSC) significantly …

Background FGFR3-altered urothelial cancer (UC) correlates with a non-T cell-inflamed
phenotype and has therefore been postulated to be less responsive to immune checkpoint …

Upper urinary tract urothelial carcinoma (UTUC) is one of the common urothelial cancers. Its
molecular pathogenesis, however, is poorly understood, with no useful biomarkers available …

The combination of targeted therapy with immune checkpoint inhibition (ICI) is an area of
intense interest. We studied the interaction of fibroblast growth factor receptor (FGFR) …

Increasing evidence indicates that success of targeted therapies in the treatment of cancer is
context-dependent and is influenced by a complex crosstalk between signaling pathways …

Background Characterization of the different genomic alterations (GAs) in urothelial
carcinoma (UC), by site of origin, may identify contrasting therapeutic opportunities and …